Fujian Genohope Biotech Ltd: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Fujian Genohope Biotech Ltd?

Yes. FDA’s import refusal records list 9 refused shipment lines declared as made by Fujian Genohope Biotech Ltd (China) whose FDA product code names tirzepatide and semaglutide, from Oct 28, 2024 to May 28, 2025. 7 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Futian
FEI numbers on the lines
3025263427
Refused lines
9
Lines with an Import Alert 66-80 API or powder code
7
Drugs named in the product codes
Tirzepatide, Semaglutide
Refusal dates
Oct 28, 2024 to May 28, 2025

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Fujian Genohope Biotech Ltd is on it.

Refused shipment lines

FDA refusal chargesShipment ID
May 28, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.BYA-2502829-1/12/1A
May 28, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.BYA-2502829-1/12/1B
Feb 28, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/1
Feb 28, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/2
Feb 28, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.BYA-2500742-8/11/3
Nov 4, 2024China61PBY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
AEK-5721091-4/11/1
Nov 4, 2024China61PBY74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
AEK-5721091-4/21/1
Oct 28, 2024China61PCS72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Further ManufNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
AEK-5719160-1/11/1
Oct 28, 2024China61PCS74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Further ManufNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).AEK-5719160-1/21/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).4
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.4
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.2
UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).2

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 5 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Fujian Genohope Biotech Ltd.”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (5).

84502-104Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTOct 17, 2024None givenDec 31, 2027Unfinished drugs
84502-101Not givensemaglutidePOWDERNot given1 g/gBULK INGREDIENTJul 2, 2024None givenDec 31, 2027Unfinished drugs
84502-109Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTOct 17, 2025None givenDec 31, 2027Unfinished drugs
84502-113Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTMay 19, 2026None givenDec 31, 2027Unfinished drugs
84502-103Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJul 31, 2024None givenDec 31, 2027Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

9 lines from FDA files read Nov 15, 2026.